Liquidia (FRA:LT4) Change In Receivables : €1.29 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Liquidia Change In Receivables?

Liquidia's change in receivables for the quarter that ended in Mar. 2025 was €1.36 Mil. It means Liquidia's Accounts Receivable declined by €1.36 Mil from Dec. 2024 to Mar. 2025 .

Liquidia's change in receivables for the fiscal year that ended in Dec. 2024 was €1.28 Mil. It means Liquidia's Accounts Receivable declined by €1.28 Mil from Dec. 2023 to Dec. 2024 .

Liquidia's Accounts Receivable for the quarter that ended in Mar. 2025 was €1.15 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Liquidia's Days Sales Outstanding for the three months ended in Mar. 2025 was 36.46.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Liquidia's liquidation value for the three months ended in Mar. 2025 was €-5.87 Mil.

Liquidia Change In Receivables Historical Data

The historical data trend for Liquidia's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Change In Receivables Chart

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-2.65

-1.91

0.88

1.28

Liquidia Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															1.37	-0.63	-0.86	1.42	1.36

Liquidia Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.29 Mil.

Liquidia (FRA:LT4) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Liquidia's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.153	/	2.886	*	91
=	36.46

2. In Ben Graham's calculation of liquidation value, Liquidia's accounts receivable are only considered to be worth 75% of book value:

Liquidia's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	157.026	-	164.387	+	0.75 * 1.153	+	0.5 * 1.248
=	-5.87

Liquidia Change In Receivables Related Terms

Thank you for viewing the detailed overview of Liquidia's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

LQDA:USA

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines